Schistosoma mansoni calpain (SmCalp (also commonly referred to as Sm-p80 for a leading vaccine candidate form))

Schistosoma mansoni calpain refers to a family of calcium-dependent cysteine proteases, notably SmCalp1 and SmCalp2, found on the external tegument of the blood fluke Schistosoma mansoni[1][5]. Unlike most calpains (which are typically intracellular in vertebrates), these calpains are surface-exposed and possess functional extracellular activity, playing a direct role at the host-parasite interface[1]. They are capable of cleaving host proteins such as fibronectin, thereby preventing blood clot formation and helping the parasite evade immune responses and clearance within the vasculature[1]. Both SmCalp1 and SmCalp2 are highly conserved in domain architecture (protease core, membrane association, and Ca2+-binding domains), but share only about 31% sequence identity, suggesting functional specialization within the parasite[1]. Sm-p80, a leading vaccine antigen, is derived from the calpain large subunit; it is the focus of vaccine and diagnostic assay development due to its immunogenicity and surface accessibility[4]. Calpain inhibitors have been shown to impair the parasite’s surface protease activity. These features make Schistosoma mansoni calpain a validated therapeutic and vaccine target for schistosomiasis[1][4][5].

Other names

SmCalp1SmCalp2Sm-p80 (calpain large subunit, vaccine antigen)

Inhibition of calpain protease activity blocks surface protein cleavage, likely impairing tegument remodeling and interfering with parasite survival by allowing blood clots to form or exposing the parasite to immune attack[1][4].